Neurology 2014-04 - Neurology Alert - Apr 01, 2014

Target Audience:

This activity is intended for the neurologist.

Accreditation:

AHC Media is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation:

AHC Media designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty Listing:

Physician Editor
Matthew Fink, MD
Professor and Chairman
Department of Neurology and Neuroscience
Weill Cornell Medical College
Neurologist-in-Chief
New York Presbyterian Hospital

Executive Editor
Leslie Coplin

Managing Editor
Neill Kimball

Peer Reviewer
M. Flint Beal, MD
Anne Parrish Titzel Professor
Department of Neurology and Neuroscience
Weill Cornell Medical Center

Assistant Editors
Michael Rubin, MD, FRCP(C)
Professor of Clinical Neurology;
Specialty area, Neuromuscular Disorders
Weill Cornell Medical College

Claire Henchcliffe, MD, PhD
Associate Professor of Neurology and Neuroscience
Weill Cornell Medical College

Dara Jamieson, MD
Associate Professor of Clinical Neurology
Weill Cornell Medical College

Alan Z. Segal, MD
Associate Professor of Clinical Neurology
Weill Cornell Medical College

Authors
Michael T. Lin, MD
Assistant Professor of Neurology and Neurosciences,
Weill Cornell Medical College

Sotirios Keros, MD, PhD
Instructor, Department of Pediatrics,
Division of Pediatric Neurology,
Weill Cornell Medical College

Susan C. Pannullo, MD, FAANS
Associate Professor of Clinical Neurological Surgery,
Director of Neuro-Oncology,
Weill Cornell Medical College

Michael Rubin, MD
Professor of Clinical Neurology,
Weill Cornell Medical College 

Bianca D. Santomasso, MD, PhD
Neuro-Oncology Fellow,
Memorial Sloan-Kettering Cancer Center,
New York, NY

Subjects:

  • Monoclonal Amyloid Antibodies for the Treatment of Alzheimer’s Disease: More Disappointment
  • ;Optic and Auditory Involvement in Demyelinating Neuropathy
  • Severe Childhood Neuronopathy that Responds to Riboflavin
  • Bevacizumab for Newly Diagnosed Glioblastoma
  • The Importance of the CSF Specimen for Antibody Determination in NMDA Receptor Encephalitis

Objectives:

  • Discuss current scientific data regarding the diagnosis and treatment of neurological disease
  • Discuss the pathogenesis and treatment of pain
  • Describe the basic science of brain function
  • Discuss new information regarding new drugs for commonly diagnosed neurological conditions

Financial Disclosure:

Neurology Alert's editor in chief, Matthew Fink, MD, is a retained consultant for Procter & Gamble. Peer reviewer M. Flint Beal, MD; executive editor Leslie Coplin; and managing editor Neill Kimball report no financial relationships relevant to this field of study.

Authors Michael T. Lin, MD, Michael Rubin, MD, Sotirios Keros, MD, PhD and Susan C. Pannullo, MD, FAANS report no financial relationships relevant to this field of study.

Author Bianca D. Santomasso, MD, PhD, reports she is a stockholder in Novartis.

Copyright 2014, AHC Media. All rights reserved.